Logo image of PRVB

PROVENTION BIO INC (PRVB) Stock Fundamental Analysis

NASDAQ:PRVB - US74374N1028 - Common Stock

24.98 USD
+0.75 (+3.1%)
Last: 4/26/2023, 8:02:36 PM
25 USD
+0.02 (+0.08%)
After Hours: 4/26/2023, 8:02:36 PM
Fundamental Rating

2

Taking everything into account, PRVB scores 2 out of 10 in our fundamental rating. PRVB was compared to 193 industry peers in the Pharmaceuticals industry. PRVB has a bad profitability rating. Also its financial health evaluation is rather negative. PRVB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PRVB had negative earnings in the past year.
In the past year PRVB has reported a negative cash flow from operations.
In the past 5 years PRVB always reported negative net income.
In the past 5 years PRVB always reported negative operating cash flow.
PRVB Yearly Net Income VS EBIT VS OCF VS FCFPRVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

PRVB has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PRVB Yearly ROA, ROE, ROICPRVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100 -150

1.3 Margins

PRVB has a better Gross Margin (96.03%) than 96.79% of its industry peers.
PRVB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRVB Yearly Profit, Operating, Gross MarginsPRVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

PRVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRVB has more shares outstanding
PRVB has a worse debt/assets ratio than last year.
PRVB Yearly Shares OutstandingPRVB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
PRVB Yearly Total Debt VS Total AssetsPRVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

PRVB has an Altman-Z score of 8.65. This indicates that PRVB is financially healthy and has little risk of bankruptcy at the moment.
PRVB has a better Altman-Z score (8.65) than 87.61% of its industry peers.
PRVB has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PRVB (0.19) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 8.65
ROIC/WACCN/A
WACC8.84%
PRVB Yearly LT Debt VS Equity VS FCFPRVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.93 indicates that PRVB should not have too much problems paying its short term obligations.
The Current ratio of PRVB (1.93) is worse than 65.60% of its industry peers.
A Quick Ratio of 1.92 indicates that PRVB should not have too much problems paying its short term obligations.
PRVB has a worse Quick ratio (1.92) than 61.47% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.92
PRVB Yearly Current Assets VS Current LiabilitesPRVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

PRVB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.09%, which is quite good.
PRVB shows a strong growth in Revenue. In the last year, the Revenue has grown by 824.37%.
EPS 1Y (TTM)12.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.76%
Revenue 1Y (TTM)824.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1408.09%

3.2 Future

Based on estimates for the next years, PRVB will show a very strong growth in Earnings Per Share. The EPS will grow by 40.69% on average per year.
Based on estimates for the next years, PRVB will show a very strong growth in Revenue. The Revenue will grow by 138.71% on average per year.
EPS Next Y-18.96%
EPS Next 2Y27.12%
EPS Next 3Y36.47%
EPS Next 5Y40.69%
Revenue Next Year372.61%
Revenue Next 2Y275.03%
Revenue Next 3Y253.14%
Revenue Next 5Y138.71%

3.3 Evolution

PRVB Yearly Revenue VS EstimatesPRVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
PRVB Yearly EPS VS EstimatesPRVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PRVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRVB Price Earnings VS Forward Price EarningsPRVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRVB Per share dataPRVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PRVB's earnings are expected to grow with 36.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.12%
EPS Next 3Y36.47%

More info and screens

0

5. Dividend

5.1 Amount

PRVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROVENTION BIO INC

NASDAQ:PRVB (4/26/2023, 8:02:36 PM)

After market: 25 +0.02 (+0.08%)

24.98

+0.75 (+3.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-04 2023-05-04/bmo
Earnings (Next)08-02 2023-08-02/bmo
Inst Owners0.27%
Inst Owner Change0%
Ins Owners7.34%
Ins Owner Change0%
Market Cap2.37B
Analysts78.33
Price Target24.48 (-2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.45%
Min EPS beat(2)3.79%
Max EPS beat(2)21.1%
EPS beat(4)4
Avg EPS beat(4)15.24%
Min EPS beat(4)3.79%
Max EPS beat(4)26.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)11.53%
Min Revenue beat(2)-4.73%
Max Revenue beat(2)27.78%
Revenue beat(4)2
Avg Revenue beat(4)2.32%
Min Revenue beat(4)-18.77%
Max Revenue beat(4)27.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)21.74%
EPS NQ rev (1m)-79.31%
EPS NQ rev (3m)-54.76%
EPS NY rev (1m)-1.57%
EPS NY rev (3m)-3.75%
Revenue NQ rev (1m)-39.66%
Revenue NQ rev (3m)-12.5%
Revenue NY rev (1m)-22.86%
Revenue NY rev (3m)-17.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 183.61
P/FCF N/A
P/OCF N/A
P/B 19.43
P/tB 38.01
EV/EBITDA N/A
EPS(TTM)-1.6
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.14
BVpS1.29
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.03%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.92
Altman-Z 8.65
F-Score2
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)1337.69%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.76%
EPS Next Y-18.96%
EPS Next 2Y27.12%
EPS Next 3Y36.47%
EPS Next 5Y40.69%
Revenue 1Y (TTM)824.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1408.09%
Revenue Next Year372.61%
Revenue Next 2Y275.03%
Revenue Next 3Y253.14%
Revenue Next 5Y138.71%
EBIT growth 1Y-10.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.94%
OCF growth 3YN/A
OCF growth 5YN/A